Leflunomide
RAS Mutation
N.N. Petrov National Medical Research Center of OncologySmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 81/ 100
Competitive context
24 Active assets in the RAS Mutation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan Tango Therapeutics, Inc. | Phase 3 | B |
FLUOROURACILUM Tango Therapeutics, Inc. | Phase 3 | B |
Cetuximab Beijing Hospital | Phase 3 | B |
Binimetinib N.N. Petrov National Medical Research Center of Oncology | Phase 2 | B |
Eloxatin Tango Therapeutics, Inc. | Phase 2 | B |
View all 25 →
Same molecule, other indications
Leflunomide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →